To further validate the regulatory role of miR-27b on MET/PI3K/AKT pathway, DLBCL cells in blank control, miR-27b mimics and miR-27b NC groups were treated with high-dose MET inhibitor Crizotinib, and MET gene expression was almost completely inhibited. This evidence concerns the gene MET and diffuse large B-cell lymphoma.